Glucono delta-lactone for treatment of vaginal fungal infections
AssigneeGedea Biotech AB
InventorsUlf Ellervik, Olov Sterner, Helena Strevens, Sophie Manner
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono δ-lactone, wherein the glucono δ-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono δ-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.
Claims17
A pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono δ-lactone (formula (III)),
- wherein the glucono δ-lactone is present in an amount of 5 to 99 wt % of the formulation.
Glucono δ-lactone (formula (III)),
- for use in the in the prevention or treatment of a fungal infection.
Dependencies are inferred from the claim text.